Drug Discovery Featured Articles & Applications

31. NAMs In France And Europe: The Current Landscape 3/20/2026

    The EU is establishing a credible and scalable NAM ecosystem, but challenges still need to be overcome before life sciences professionals and patients can reap the benefits.

32. Rethinking Tau Biology: The Future Of Neurodegenerative Drug Discovery 3/19/2026

    We caught up with Melissa Murray, Ph.D., and Amy Rommel, Ph.D., to discuss tau-associated neurodegenerative diseases.

33. Proteomics Biomarkers Beyond Blood 3/16/2026

    Effective biomarker strategies have the potential to accelerate decision-making, de-risk development, and help drive precision medicine.

34. MicroRNA Therapeutics In Metabolic Liver Disease: Context-Driven Drug Discovery 3/12/2026

    Realizing the therapeutic potential of miRNAs in liver disease requires confronting a problem the field has not fully reckoned with.

35. Viral Coinfections: Emerging Challenges In Modern Drug Discovery 3/11/2026

    Viral coinfection is a phenomenon more complex than just the concurrency or sequential infection with multiple viruses in the same host. 

36. Execution Debt In Early Drug Discovery: The Hidden Risk That Undermines Promising Biology 3/10/2026

    Understanding how execution debt forms, how it compounds, and how to prevent it is central to building durable discovery programs.

37. Hope For Non-Hallucinogenic Neuroplastogens 3/9/2026

    We caught up with Joseph Tucker, Ph.D., to discuss Enveric Bioscience’s focus on developing non-hallucinogenic neuroplastogenic compounds.

38. The Future Of Kidney Disease Therapeutics: Bringing Nanomedicine To Nephrology 3/6/2026

    Nanomedicines are solving the drug delivery problem in kidney disease. The next step: bridging the translational gap to advance these technologies into the clinic.

39. Injecting Cancer Killers: Intratumoral Therapy For Solid Tumors 3/5/2026

    Intratumoral injection bypasses the tumor’s physical defenses entirely, killing cancer cells and creating a personalized immune response that destroys solid tumors.

40. The Advantages Of Antibodies Over Ligands In The Alpha Emitter Era 3/5/2026

    The alpha era in radiopharmaceuticals is still being defined. The choices developers make now about delivery platforms will shape individual programs and the trajectory of the field.